PDCD1 and cancer: For instance, evidence has shown that CTLA4 inhibitors combined with PD-1 or PD-L1 agents can bring about higher incidence and severity of irAEs, such as the combination of ipilimumab and nivolumab, irrespective of the primary cancer treated [132,133,134].